Pomalidomide
Brand name: Pomalyst
Rank #31 of 500 drugs by total cost
$589.0M
Total Cost
27,253
Total Claims
$589.0M
Total Cost
1,082
Prescribers
$22K
Cost per Claim
1,779
Beneficiaries
27,261
30-Day Fills
$544K
Avg Cost/Provider
25
Avg Claims/Provider
About Pomalidomide
Pomalidomide (sold as Pomalyst) was prescribed 27,253 times by 1,082 Medicare Part D providers in 2023, costing the program $589.0M. At $22K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology